Why Experts Say This New Weight Loss Drug Could Be a Game Changer

From Ozempic to Wegovy to Mounjaro, injectable weight-loss drugs have become household names — and now there’s a new one everyone is talking about. 

Retatrutide, a once-weekly experimental injection, is generating buzz for its potential to outperform current medications by a wide margin. Experts say its unique approach to targeting multiple hormones could be a game-changer for obesity treatment.

Jennifer Brown, MD, ABOM, ABFM, tells Life & Style that Retatrutide works differently from currently available weight-loss drugs. 

“Retatrutide is a new once-weekly experimental weight-loss injection developed by Eli Lilly. It’s a triple agonist drug, meaning it targets three separate hormonal pathways to treat obesity,” she explains. “It targets GLP-1, GIP, and glucagon receptors. In comparison, semaglutide targets only GLP-1 receptors, whereas tirzepatide targets both GLP-1 and GIP receptors.”